The DCAT Pulse: The Tariff Outlook & Pharma

Evolving US tariff policy is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharma companies and their suppliers. A DCAT webinar gives an executive briefing on what is crucial to consider in supply planning amid tariff uncertainty.

Evolving US tariff/trade policy is top of mind for the bio/pharma industry and is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharmaceutical companies and their suppliers. Unpacking what tariffs are in place, and what additional tariffs may come to be and how they will be implemented is a challenge unto itself, but an even greater challenge is how can companies put forth effective supply plans amid such tariff uncertainty?

To address that critical question, a DCAT webinar, The Tariff Outlook & Pharma, airing January 22, 2026 (10:00-10:30 AM EST-US), brings together leading industry experts on what may lie ahead in 2026 and what is important to consider in effective supply planning. Jens Charlieson, Head of Transport & Trade Compliance at Swedish Orphan Biovitrum AB (Sobi), and Gabriela de Almeida, Managing Director and Partner at Boston Consulting Group, will share key insights on the crucial factors and scenarios to consider for effective supply planning and trade compliance.

The webinar is part of The DCAT Pulse, a new, member-focused insights hub from the Drug, Chemical & Associated Technologies Association (DCAT) that brings together fresh perspectives and seasoned expertise, spotlighting trends and opportunities that help DCAT Member Companies stay informed, engaged, and ahead of the curve in a dynamic marketplace.

The webinar, The Tariff Outlook & Pharma, was developed by the volunteer DCAT Supply Management Committee, composed of senior to mid-level executives involved in sourcing, procurement and supply management. The webinar is provided exclusively and complimentary to all employees of DCAT Member Companies, who can register here. Not able to attend the webinar on January 22? No problem. The webinar will be available for on-demand viewing, but you must register to view.

Recent Feature Articles

Blockbuster Contenders: The Class of 2026

By
What new products, recently or expected to launch in 2026, show blockbuster potential or will be transformative in key therapeutic areas? A look at the companies and products rising to the top of the class. 

CDMOs Roll Out Expansions for Parenteral Drugs

By
The global injectables drugs market is projected for strong growth, driven by demand in biologics and specialty therapeutics. In response, CDMOs/CMOS are expanding production capacity. What are the latest expansions?

Big Pharma Outlook: CEOs Making the Moves

By
As the industry moves further into 2026, what are larger issues impacting industry and company performance? .A view from the C-suite.

Industry Radar: What’s Next in US Drug Pricing

By
A bevy of news on the US drug pricing front: the debut of TrumpRx, a direct-to-patient drug purchasing channel, continued policy moves to most favored drug nation pricing, reforms of PBMs, and the latest in IRA